Yanada Masamitsu, Harada Kaito, Shimomura Yoshimitsu, Arai Yasuyuki, Konuma Takaaki
Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
Front Oncol. 2022 Nov 25;12:1050633. doi: 10.3389/fonc.2022.1050633. eCollection 2022.
Conditioning regimens play a crucial role in preventing relapse of acute myeloid leukemia (AML) following allogeneic hematopoietic cell transplantation (HCT). In early times, myeloablative conditioning was used exclusively, but it was associated with significant toxicity. However, the advent of reduced-intensity conditioning has allowed allogeneic HCT to be performed more safely, leading to an expansion of our choices for conditioning regimens. As the transplantation methods have become highly diversified, it is reasonable to determine an optimal conditioning regimen in consideration of patient-, disease-, and transplantation-related factors. In this context, large-scale registry-based studies provide real-world data to allow for a detailed evaluation of the utility of individual conditioning regimens in specific clinical settings. The Japanese Society for Transplantation and Cellular Therapy has been conducting a nationwide survey for HCT since 1993 that currently covers >99% of all the transplantation centers nationwide, and >1,000 allogeneic HCTs performed for adults with AML are registered per year. We have been using the registry data to implement a number of studies focusing on adults with AML, and the large number of patients registered consecutively from nearly all transplantation centers nationwide represent real-world practice in Japan. This article reviews and discusses the results obtained from our registry-based studies pertaining to various conditioning regimens.
预处理方案在异基因造血细胞移植(HCT)后预防急性髓系白血病(AML)复发中起着关键作用。早期,仅使用清髓性预处理,但它与显著的毒性相关。然而,减低强度预处理的出现使异基因HCT能够更安全地进行,从而扩大了我们对预处理方案的选择范围。随着移植方法变得高度多样化,考虑患者、疾病和移植相关因素来确定最佳预处理方案是合理的。在此背景下,基于登记处的大规模研究提供了真实世界的数据,以便在特定临床环境中详细评估各个预处理方案的效用。日本移植与细胞治疗学会自1993年以来一直在全国范围内对HCT进行调查,目前覆盖全国所有移植中心的99%以上,每年有超过1000例为成年AML患者进行的异基因HCT登记。我们一直在使用登记数据开展多项针对成年AML患者的研究,几乎来自全国所有移植中心连续登记的大量患者代表了日本的真实世界实践。本文回顾并讨论了我们基于登记处的研究中关于各种预处理方案所获得的结果。